Leila Godfrey
Postdoctoral Immunologist
Immunologist for the Oxford AstraZeneca Covid-19 vaccine clinical trial. Previous academic role working on projects using the multiomics platform BD Rhapsody in The Diabetes and Inflammation Laboratory, University of Oxford. Industry experience in T Cell Receptor Biotechnology for cancer therapies at Immunocore. Doctoral research on the role of Natural Killer Cells in autoimmune arthritis
Recent publications
-
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Journal article
Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209
-
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials
Journal article
EWER K., (2023), Clinical and Experimental Immunology
-
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Journal article
Mentzer AJ. et al, (2023), Nat Med, 29, 147 - 157
-
Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination.
Journal article
Foster WS. et al, (2022), Cell Rep Med
-
Low-dose IL-2 reduces IL-21+ T cell numbers and induces anti-inflammatory gene expression in type 1 diabetes
Journal article
Zhang J. et al, (2022), Nature Communications